Ma: Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients

Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients

Ma et al., AACR Annual Meeting 2022 (In Vitro)

8 Apr 2022 Source PDF Share Tweet

Review of the mechanisms of action of proxalutamide for COVID-19, and In Vitro results showing that proxalutamide inhibited SARS-CoV-2 wild type, alpha and delta variants, with IC₅₀ of 69, 48 and 39nM. Only the abstract is currently available.

Important missing comments or errors? Let us know.

Ma et al., 8 Apr 2022, peer-reviewed, 12 authors.

In Vitro studies are an important part of preclinical research, however results may be very different in vivo.

All Studies All Outcomes Submit Updates or Corrections

This Paper Proxalutamide All

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit